Anti-Inflammatory Therapeutics Market Size to Reach USD 213.4 Billion by 2036, Growing at a 6.1% CAGR Driven by Rising Chronic Disease Prevalence and Advancements in Targeted Biologics

Anti-inflammatory therapeutics are medicines designed to control excessive inflammation while preserving the body's beneficial immune responses. The market includes nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, biologics, disease-modifying antirheumatic drugs (DMARDs), and other targeted therapies.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1907

The global anti-inflammatory therapeutics market was valued at USD 111.4 billion in 2025 and is forecast to reach USD 213.4 billion by 2036. The market is expected to grow at a CAGR of 6.1% between 2026 and 2036. Rising treatment needs for arthritis, asthma, psoriasis, inflammatory bowel disease, multiple sclerosis, and other chronic inflammatory conditions are supporting long-term demand.

Market Overview

The market is being transformed by a shift from conventional symptom management toward targeted and disease-specific therapies. Pharmaceutical and biotechnology companies are increasing investments in biologics, molecular targets, immunomodulators, and next-generation treatment platforms.

Arthritis accounted for the largest indication share of 32.6% in 2025, supported by the high prevalence of rheumatoid arthritis, osteoarthritis, and related conditions requiring long-term disease management. North America led the global market with a 37.3% revenue share in 2025, supported by advanced healthcare infrastructure, high treatment adoption, strong pharmaceutical capabilities, and favorable access to innovative medicines.

Key Drivers of Market Growth

The rising prevalence of chronic inflammatory diseases is the primary growth driver. Increasing cases of arthritis, asthma, psoriasis, inflammatory bowel disorders, and autoimmune diseases are creating a large patient base requiring continuing treatment.

Population aging is another important factor. Older adults have a higher risk of chronic inflammatory and musculoskeletal conditions, increasing the need for long-term disease management and symptom control.

Strong pharmaceutical R&D investment is also accelerating market expansion. Companies are developing biologics and targeted therapies that aim to improve efficacy while reducing unwanted effects associated with traditional medicines. Advances in biotechnology, genomics, and molecular research are enabling researchers to identify new inflammatory pathways and therapeutic targets.

Increasing healthcare expenditure and improved diagnosis in emerging economies are further expanding access to anti-inflammatory treatments. Greater awareness of early diagnosis and disease management is also encouraging patients to seek treatment sooner.

Key Players and Industry Leaders

The competitive landscape includes major pharmaceutical and biotechnology companies with extensive research capabilities, established product portfolios, and global distribution networks. Key players include Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Johnson & Johnson and its affiliates, Amgen Inc., Pfizer Inc., GSK plc, Novartis AG, Merck & Co., Inc., Dr. Reddy’s Laboratories, AdvaCare Pharma, Viatris Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd.

Competition is increasingly focused on innovative drug development, strategic partnerships, clinical research, biosimilar expansion, and geographic market access. Mergers and acquisitions also provide companies with opportunities to strengthen pipelines and accelerate commercialization.

Key Trends for the Future

A major future trend is the increasing adoption of biologics and targeted therapies. These treatments can address specific inflammatory mechanisms and provide alternatives for patients who do not respond adequately to conventional medicines.

Precision medicine is also gaining importance as pharmaceutical developers use genetic, molecular, and patient-specific information to improve treatment selection. Biosimilars are expected to support broader access to advanced therapies by increasing competition and potentially reducing treatment costs.

Digital healthcare and improved diagnostic technologies will further influence treatment pathways. Earlier disease identification can increase the addressable patient population and support more effective long-term disease management.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/anti-inflammatory-therapeutics-market.html

New Opportunities and Challenges

Rare inflammatory diseases represent an important untapped opportunity. Many rare autoimmune and inflammatory conditions have limited treatment options, creating demand for specialized therapies. Advances in genomics, biotechnology, and diagnostics are improving researchers' ability to identify disease mechanisms and develop targeted treatments.

Orphan drug incentives can encourage pharmaceutical companies to invest in rare-disease programs. However, high development costs, complex clinical trials, regulatory requirements, and limited patient populations remain significant challenges.

Safety concerns, pricing pressure, reimbursement restrictions, and competition from generic and biosimilar products can also affect market profitability. Companies must balance innovation with affordability and patient access.

Market Trends & Innovations

Innovation is moving toward therapies that provide better efficacy, longer treatment duration, and improved safety profiles. New molecular targets and advanced biologics are expanding therapeutic possibilities across autoimmune and inflammatory diseases.

Recent industry developments demonstrate continued activity. In April 2025, Strides Pharma received U.S. FDA approval for celecoxib capsules in 100 mg, 200 mg, and 400 mg strengths. In February 2025, Kiora Pharmaceuticals announced a U.S. patent covering a crystalline form of KIO-104, a novel non-steroidal anti-inflammatory small-molecule DHODH inhibitor. In April 2024, Glenmark Pharmaceuticals received U.S. regulatory approval for a generic anti-inflammatory medicine.

These developments highlight the importance of both innovative therapies and cost-effective generic medicines in the evolving market.

Future Outlook

The anti-inflammatory therapeutics market is expected to maintain positive momentum through 2036. Growth will be supported by expanding patient populations, rising healthcare expenditure, improved diagnosis, and continuous pharmaceutical innovation.

North America is likely to remain a major market because of its strong research ecosystem, healthcare infrastructure, reimbursement systems, and early adoption of biologics and targeted therapies. Meanwhile, Asia Pacific and other emerging markets offer substantial expansion potential as healthcare access improves and government-supported healthcare programs expand.

Companies that combine innovative R&D with strategic partnerships, biosimilar development, efficient commercialization, and emerging-market expansion are likely to gain competitive advantages.

Market Segmentation

By Drug Class: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Biologics, and Others including DMARDs and analgesics.

By Indication: Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Disease (IBD), and Others.

By Route of Administration: Oral, Topical, Injectable, Inhalation, and Others including transdermal delivery.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Region: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=1907<ype=S

Important FAQs with Answers

What was the size of the anti-inflammatory therapeutics market in 2025?

The global market was valued at USD 111.4 billion in 2025.

What will the market reach by 2036?

The market is projected to reach USD 213.4 billion by 2036.

What is the expected market CAGR?

The market is forecast to expand at a CAGR of 6.1% from 2026 to 2036.

Which indication held the largest market share in 2025?

Arthritis led the market with a 32.6% share.

More Trending Reports by Transparency Market Research –

Natural APIs Market: https://www.transparencymarketresearch.com/natural-apis-market.html

PCSK9 Inhibitor Market: https://www.transparencymarketresearch.com/pcsk9-inhibitors-market.html

Neuroprotection Market: https://www.transparencymarketresearch.com/neuroprotection-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com